Table: Taisho Pharmaceutical HD - 6-MTH group results
Nov 9 (Reuters)-
Taisho Pharmaceutical Holdings Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
6 months ended 6 months ended Year to
Sep 30, 2021 Sep 30, 2020 Mar 31, 2022
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 130.16 145.90 269.00
(-10.8 pct) (+10.4 pct) (-4.6 pct)
Operating 2.31 16.30 14.50
(-85.8 pct) (+12.2 pct) (-27.4 pct)
Recurring 4.22 18.86 18.50
(-77.6 pct) (+29.1 pct) (-28.7 pct)
Net 2.91 11.29 10.50
(-74.3 pct) (-23.6 pct) (-21.1 pct)
EPS 35.95 yen 141.51 yen 131.45 yen
EPS Diluted 35.90 yen 141.34 yen
Ann Div 100.00 yen 100.00 yen
-Q2 div 50.00 yen 50.00 yen
-Q4 div 50.00 yen 50.00 yen
NOTE - Taisho Pharmaceutical Holdings Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4581.T
Recent news on Taisho Pharmaceutical Holdings Co
See all newsBrief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Squeeze Out Price If Taisho Disagrees With Their Demand - Nikkei
Brief: Curi RMB Capital, Kaname Capital To Request Tokyo Court To Revise Taisho Pharmaceutical's Tender Offer Price If Taisho Disagrees Their Demand - Nikkei
Activist fund Oasis says it may take legal action over Taisho's management buyout
Brief: Curi RMB Capital Opposes Taisho Pharmaceutical HD's Management Buyout
To Retire Treasury Shares Worth 3.65% Of Outstanding Stock On April 10